AU
UK
CA
NZ
IND
US
INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company developing DNA medicines targeting HPV-related diseases, cancer, and infectious diseases, announced its plans to conduct a public offering of its common stock. All shares in the offering will be sold by the company, which will also grant …
Precision BioSciences, Inc. (NASDAQ:DTIL)reported new findings from its ongoing Phase 1 ELIMINATE-B study of PBGENE-HBV at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. PBGENE-HBV is an in vivo gene editing therapy designed to target HBV cccDNA and …
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)released its financial results for Q3 2025 and shared an operational update. The US launch of EKTERLY® (sebetralstat) began on July 7, 2025. By October 31, 2025, the company had received 937 patient start forms and activated 423 unique prescribers.
Innate Pharma SA (NASDAQ:IPHA) announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL). The FDA had no further comments, allowing the trial to proceed.
Organon (NYSE:OGN)reported findings from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 trials at the 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting. The analysis assessed VTAMA® (tapinarof) cream, 1%, in children aged 2-17 with …
Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, released results from the pivotal Phase 3 CORALreef HeFH trial at the American Heart Association Scientific Sessions 2025. The study assessed enlicitide decanoate, an investigational once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, …
Edwards Lifesciences (NYSE:EW)has announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a nationwide effort to enhance care and outcomes for approximately 28 million people worldwide living with heart valve disease. In the U.S., valve disease contributes to over 60,000 deaths …
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) released its financial results for the third quarter ended September 30, 2025, along with updates on recent strategic developments. The company, which focuses on oral delivery of biologics through its RaniPill® technology, highlighted new collaborations and capital inflows aimed …
Dexcom, Inc. (NASDAQ:DXCM)a global company specializing in continuous glucose monitoring technology, announced that the Québec government has extended public health coverage for its CGM systems under the Régie de l’assurance maladie du Québec. The update now includes eligible adults aged 18 and older with …
ImmunityBio, Inc. (NASDAQ:IBRX), a biotechnology firm advancing immunotherapies and cell-based treatments for cancer and infectious diseases, announced its financial and operational results for the third quarter and nine months ended September 30, 2025.
Please wait processing your request...